Followers | 170 |
Posts | 10014 |
Boards Moderated | 3 |
Alias Born | 06/20/2022 |
Friday, March 15, 2024 7:28:18 PM
"Bristol Myers, 2seventy Bios Cancer Treatment Wins FDA Committee Approval
7:04 PM ET 3/15/24 | Dow Jones
By Ben Glickman Bristol Myers Squibb and 2seventy Bio's cancer treatment showed a favorable risk-benefit profile in certain populations, according to Food and Drug Administration committee. The Oncologic Drugs Advisory Committee voted 8-3 that Abecma, a gene therapy, had a favorable profile in the treatment of the blood cancer multiple myeloma, specifically in the triple-class exposed relapsed or refractory forms of the cancer, the companies said on Friday. Bristol Myers Squibb and 2seventy said the recommendation would be considered by the FDA in its review of their supplemental Biologics License Application. The FDA hasn't assigned a new target action date for reviewing that application, the companies said. Abecma was recently approved in Japan and Switzerland for patients with relapsed or refractory multiple myeloma who have received at least two prior therapies. Write to Ben Glickman at ben.glickman@wsj.com > Dow Jones Newswires March 15, 2024 19:04 ET (23:04 GMT)"
Recent TSVT News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:03:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 11:09:06 AM
- 2seventy bio Reports First Quarter Financial Results and Recent Operational Progress • Business Wire • 05/08/2024 11:00:00 AM
- 2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024 • Business Wire • 05/03/2024 11:00:00 AM
- U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy • Business Wire • 04/05/2024 01:05:00 PM
- 2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron • Business Wire • 04/01/2024 11:30:00 AM
- 2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors • Business Wire • 03/20/2024 09:04:00 PM
- FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy • Business Wire • 03/15/2024 10:27:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/07/2024 09:02:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 12:03:51 PM
- 2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress • Business Wire • 03/05/2024 12:00:00 PM
- 2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences • Business Wire • 03/01/2024 12:00:00 PM
- 2seventy bio to Participate in Upcoming Investor Conferences • Business Wire • 02/05/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 12:02:03 PM
- Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study • Business Wire • 02/05/2024 11:59:00 AM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 02/02/2024 09:54:43 PM
- Biotech Shares Soar Premarket On Sale Of R&D Assets • AllPennyStocks.com • 01/30/2024 02:25:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 12:48:56 PM
- 2seventy bio Announces New Strategic Path Forward • Business Wire • 01/30/2024 12:01:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/05/2024 09:31:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 12:25:43 PM
- Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3 • Business Wire • 12/12/2023 12:30:00 AM
- 2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel) • Business Wire • 12/11/2023 12:00:00 PM
- 2seventy bio Reiterates Commitment to Maximizing Shareholder Value • Business Wire • 12/06/2023 07:00:00 PM
- Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 12/01/2023 11:49:54 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM